Actively Recruiting
Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma
Led by Sun Yat-sen University · Updated on 2024-02-21
38
Participants Needed
1
Research Sites
139 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Cadonilimab, a tetravalent bispecific antibody targeting PD-1 and CTLA-4, is designed to retain the efficacy benefit of combination of PD-1 and CTLA-4 and improve on the safety profile of the combination therapy. The aim of this study is to evaluate the efficacy and safety of cadonilimab in combination with bevacizumab and standard chemotherapy as first Line therapy in unresectable pleural mesothelioma.
CONDITIONS
Official Title
Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed pleural malignant mesothelioma not eligible for curative surgery
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- No previous systemic anti-tumor treatment for advanced/metastatic disease
- Measurable disease as per mRECIST v1.1 for assessment of response in malignant pleural mesothelioma
- Adequate haematological, renal and liver function
You will not qualify if you...
- Primitive peritoneal, pericardial and tunica vaginalis testis mesothelioma
- Active, untreated central nervous system (CNS) metastasis
- Use of Chinese herbal medicine or immunomodulatory agents with anti-tumor indications within 14 days prior to the first dose of study treatment
- Known active autoimmune diseases
- Presence of other uncontrolled serious medical conditions
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Actively Recruiting
Research Team
W
Wenfeng Fang, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here